Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Aman Wadhwa
Instructor
Close
E-mail
awadhwa@uab.edu
Visualizations
Co-investigator Network
Aman Wadhwa
Instructor
Positions
Instructor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
2019 -
Research
Background
Contact
Research
Principal Investigator On
Body Composition and Outcomes in Childhood Cancer
awarded by
St. Baldrick's Foundation
2019 - 2021
Body Composition and Adverse Outcomes in Childhood Cancer
awarded by
KAUL PEDIATRIC RESEARCH INSTITUTE
2020 - 2021
Investigator On
AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2020 - 2026
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Private Grant
awarded by
BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
2020 - 2025
AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2024
AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2022
Project EveryChild APEC14B1
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2021
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2015 - 2021
A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2014 - 2020
Body Composition and Adverse Outcomes in Childhood Cancer
awarded by
KAUL PEDIATRIC RESEARCH INSTITUTE
2019 - 2020
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2019
Body Composition and Outcomes in Childhood Cancer
awarded by
St. Baldrick's Foundation
2019
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2019
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2014 - 2018
Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2013 - 2017
CTSU: Phase II Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2012 - 2017
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2014 - 2015
Background
Education And Training
Bachelor of Medicine & Surgery (MBBS),
Rajiv Gandhi University of Health Sciences
2012
Contact
Full Name
Aman
Wadhwa